Table 1.
Clinical characteristics of the treated and untreated groups.
| Treated Groups (n = 39) | Untreated Group (n = 216) | |
|---|---|---|
| Median Age, (Q1, Q3) | 57.9 (49.6, 65.8) | 58.6 (53.2, 66.0) |
| Female Patients, n (%) | 27 (69.2) | 155 (71.8) |
| Patients w/ MS, n (%) | 30 (76.9) | 202 (93.5) |
| Patients w/ NMOSD, n (%) | 8 (20.5) | 8 (3.7) |
| Patients w/ MOGAD, n (%) | 1 (2.6) | 6 (2.8) |
| Patients w/ Other Major Comorbidities, n (%) | 33 (84.6) | 157 (72.7) |
| Patients w/ History of Rituximab Use, n (%) | 32 (82.1) | 100 (46.3) |
| Patients w/ History of Ocrelizumab Use, n (%) | 16 (41.0) | 156 (72.2) |
| Patients w/ History of Ofatumumab Use, n (%) | 0 | 7 (3.2) |
| Median Baseline Level of Hypogammaglobulinemia during B-cell Therapy (mg/dl) | 537 (438, 619) | 591 (534, 641) |
| Patients w/ Hypogammaglobulinemia Before Starting B-cell Therapy, n (%) | 7 (17.9) | 53 (24.5) |
| Patients w/ Infections During B-cell Therapy (before the treatment for hypogammaglobulinemia in treated groups), n (%) | 27 (69.2) | 53 (24.5) |
| Outcomes | ||
| Patients who Relapsed During Treatment for Hypogammaglobulinemia, n (%) | 1 (2.6) | N/A |
| Patients w/ B-cell Repopulation During Treatment for Hypogammaglobulinemia, n (%) | 4 (10.3) | N/A |
| Median Follow-up Time During Treatment for Hypogammaglobulinemia (months) | 22.4 (11.8, 31.1) | N/A |